Newsletter Subscription


Friday, Oct 24, 2014


Implant Sciences Sells Explosives Detection Equipment to Major European Airline; Major European Airline to Use Quantum Sniffer Handheld Explosives Detection Equipment for Security Applications

(WAKEFIELD, Mass., August 25, 2005) -- Implant Sciences Corporation (AMEX: "IMX", "IMX.WS") a developer and manufacturer of products for national security, medicine and industry, today announced orders for two (2) units of our Quantum Sniffer handheld explosives detection equipment to be shipped to a major European Flag Airline. The two (2) handheld explosives detection units have been ordered by the airline for security screening purposes. To date, orders for over 150 Quantum Sniffers have been received by the Company worldwide.

Dr. Anthony J. Armini, PhD., CEO of Implant Sciences, commented, "This order marks our first commercial sale to a major airline operator. As anticipated, over the past several weeks, we have reported increasing activity in orders for our Quantum Sniffer explosives detection equipment. We believe we are now beginning to reap the benefits of the hard work of our direct and indirect sales force that, over the past year, were charged with introducing a new explosives detection technology and product into a highly competitive marketplace."

Related Research on ASDReports.com:
The Global CBRN Defense Market 2013-2023

About Implant Sciences
Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for the homeland security, semiconductor and medical device industries. The Company has developed and commercialized portable and bench-top trace element detection devices to identify explosives. In addition, to its other cancer treatment products the Company recently received an FDA 510k approval for its new radioactive source for the use in the treatment of breast cancer.

Implant Sciences believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission.


Contact:
Aurelius Consulting Group:
Dave Gentry, 407-644-4256
dave@aurcg.com
www.runonideas.com
or
Implant Sciences Corporation:
Anthony Armini, 781-246-0700
aarmini@implantsciences.com
www.implantsciences.com

Source : Implant Sciences Corporation

Published on ASDNews: Aug 26, 2005

 

© 2004-2014 • ASDNews • be the first to know • contact usterms & conditionsprivacy policyadvertisingfaqs